Full-Time

Financial Accountant

Posted on 3/20/2025

Icon

Icon

10,001+ employees

Consulting and development services for pharmaceuticals

No salary listed

Mid

Company Does Not Provide H1B Sponsorship

Chennai, Tamil Nadu, India + 1 more

More locations: Thiruvananthapuram, Kerala, India

Hybrid role (Chennai or Trivandrum)

Category
Financial Accounting
Financial Analysis
Management Accounting
Accounting
Required Skills
Financial analysis
Excel/Numbers/Sheets
Requirements
  • Qualified / Semi Qualified Professionals – CA / ACA / CIMA / ACCA.
  • Should have experience in R2R, GL, P&L, VAT, Reconciliations, Financial Statement
  • 2 years PQE with accounts preparation experience.
  • Confident using Excel to an advanced level.
  • Comfortable using systems. If you have Oracle Financials that would be a bonus.
  • Excellent interpersonal skills with the ability to convert financial data to understandable information.
  • Ability to work on own initiative.
  • An outstanding team member and partner to ICON.
Responsibilities
  • Managing day-to-day financial transactions, including accounts payable and receivable.
  • Assisting in the preparation of financial statements, including balance sheets and income statements.
  • Conducting financial analysis to support decision-making processes and identify areas for improvement.
  • Ensuring compliance with accounting standards and regulations.
  • Collaborating with cross-functional teams to support financial reporting and analysis.

Icon provides consulting, development, and commercialization services to help clients in the pharmaceutical and medical device industries accelerate the creation of products that enhance health and well-being. Their services are designed to streamline the process of bringing drugs and devices to market by focusing on reducing time and costs while improving quality. With a presence in 53 countries, Icon has a global team of experts who specialize in various therapeutic areas, allowing them to offer tailored solutions to meet the specific needs of their clients. The company's goal is to support the development of life-saving products and improve the quality of life for patients.

Company Size

10,001+

Company Stage

IPO

Headquarters

Ireland

Founded

1990

Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Mural Health enhances trial participant management and engagement.
  • Increased AI use in biomarker detection boosts ICON's neurodegenerative research capabilities.
  • Barry Balfe's appointment as COO strengthens ICON's operational excellence and growth potential.

What critics are saying

  • Securities fraud lawsuit poses financial and reputational risks for ICON.
  • Complexity in multi-indication trials may lead to inefficiencies in clinical development.
  • Underutilization of biomarkers in trials could hinder ICON's research efficiency.

What makes Icon unique

  • ICON's global network spans 53 countries, offering comprehensive clinical research services.
  • Focus on reducing time to market, cost, and increasing quality sets ICON apart.
  • ICON's expertise in multi-indication studies enhances its competitive edge in clinical trials.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

401(k) Retirement Plan

Mental Health Support

Life Insurance

Flexible Work Hours

Company News

BioSpace
May 7th, 2025
Global ICON survey shows need for more efficient obesity clinical trial design to realise full potential of next-gen multi-indication therapies

Alongside the whitepaper, ICON has launched their new Centre for Obesity that delivers expertise and market intelligence with a ready-to-deploy infrastructure of 100 sites and an in-development database of 10,000 pre-screened patients across the breadth of comorbidities related to obesity.

PharmiWeb
May 7th, 2025
Global Icon Survey Shows Need For More Efficient Obesity Clinical Trial Design To Realise Full Potential Of Next-Gen Multi-Indication Therapies

Dublin, Ireland – 7 May – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of 155 biotech and pharma professionals from across the US and Europe focusing on multi-indication cardiometabolic RD for therapies targeting obesity and its comorbidities. Multi-indication studies are clinical trials that test how a treatment works for more than one condition or disease. As researchers uncover the potential of particular drug classes across interconnected diseases, the commercial opportunities have increased the appetite for additional research that targets multiple indications. The findings indicate that most sponsors (83% of respondents) are pursuing multi-indication approaches in their obesity-related research. However, the survey results also suggest that sponsors may underestimate the complexity of these strategies - particularly when selecting inclusion criteria and endpoints - which can lead to inefficiencies in the clinical development process

Broad Street Hero
Apr 3rd, 2025
An old friend joins the Broadstreet team

After Oxford Outcomes was acquired by ICON Plc. she honed her expertise in real world evidence (RWE), spending a lot of her time on multi-national projects including prospective studies, retrospective database and chart reviews, and eliciting patient, caregiver and provider perspectives.

Rewbix
Mar 21st, 2025
Legal Turmoil for ICON Public Limited Company (ICLR): A Deep Dive into the Financial Impact of Securities Fraud Lawsuit

ICON Public Limited Company (ICLR), a leading healthcare and pharmaceutical services provider, has been hit by a securities fraud class-action lawsuit.

Rewbix
Mar 16th, 2025
Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company (ICLR)

The law firm Kessler Topaz Meltzer & Check, LLP announced on March 16, 2025, that it has filed a securities fraud class action lawsuit against ICON Public Limited Company (ICLR).

INACTIVE